Safety survey of intranasal glutathione

Journal of Alternative and Complementary Medicine

Volumn 19, Issue 5, 2013, Pages 459-463

  Mischley, Laurie K ^a   Vespignani, Marco F ^a   Finnell, John S ^a  

^a BASTYR UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE;

ADULT; AGED; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEALTH CARE SURVEY; HUMAN; LYME DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CHEMICAL SENSITIVITY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT SATISFACTION; PERSONAL EXPERIENCE; POPULATION; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINUSITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; FEMALE; GLUTATHIONE; HUMANS; MALE; MIDDLE AGED; MULTIPLE CHEMICAL SENSITIVITY; NASAL SPRAYS; PARKINSON DISEASE; PATIENT SATISFACTION; PRODUCT SURVEILLANCE, POSTMARKETING; RESPIRATORY HYPERSENSITIVITY; SINUSITIS; YOUNG ADULT;

EID: 84877311992     PISSN: 10755535     EISSN: 15577708     Source Type: Journal    
DOI: 10.1089/acm.2011.0673     Document Type: Review

References (27)

1. Mueller SG, Trabesinger AH, Boesiger P, Wieser HG. Brain glutathione levels in patients with epilepsy measured by in vivo (1)H-MRS. Neurology 2001;57:1422-1427.
2. Prousky J. The treatment of pulmonary diseases and respiratory- related conditions with inhaled (nebulized or aerosolized) glutathione. Evid Based Complement Alternat Med 2008;5:27-35.
3. Schulz JB, Lindenau J, Seyfried J, Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem FEBS 2000;267:4904-4911.
4. Wu G, Fang YZ, Yang S, et al. Glutathione metabolism and its implications for health. J Nutr 2004;134:489-492.
5. Sims NR, Nilsson M, Muyderman H. Mitochondrial glutathione: A modulator of brain cell death. J Bioenerg Biomembr 2004;36:329-333.
6. Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol 2000;62:649-671.
7. Mischley LK. Glutathione deficiency in Parkinson's disease: Intranasal administration as a method of augmentation. J Orthomol Med 2011;26:1-5.
8. McMartin C, Hutchinson LE, Hyde R, Peters GE. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J Pharm Sci 1987;76: 535-540.
9. Collier C. Count so far. In: Mischley L, ed. Email communication regarding update on the number of individuals identified thus far who have received a prescription for intransally- administered glutathione. Seattle, WA, 2011.
10. Eagle Analytical Services. Laboratory Report: Glutathione 200mg/mL.Houston, 2011. Contract No.: Sample ID #: 248260.
11. Seymour J. In: Mischley LK, ed. Use of compounded glutathione by CAM practitioners in the Pacific Northwest. [personal communication] Las Vegas, NV, 2007.
12. Brown MM, Jason LA. Functioning in individuals with chronic fatigue syndrome: Increased impairment with cooccurring multiple chemical sensitivity and fibromyalgia. Dyn Med 2007;6:6.
13. Sorg BA. Multiple chemical sensitivity: Potential role for neural sensitization. Crit Rev Neurobiol 1999;13:283-316.
14. Pall ML. Elevated nitric oxide/peroxynitrite theory of multiple chemical sensitivity: Central role of N-methyl-D-aspartate receptors in the sensitivity mechanism. Environ Health Perspect 2003;111:1461-1464.
15. De Luca C, Scordo MG, Cesareo E, et al. Biological definition of multiple chemical sensitivity from redox state and cytokine profiling and not from polymorphisms of xenobiotic-metabolizing enzymes. Toxicol Appl Pharmacol 2010;248:285-292.
16. Inomata N, Osuna H, Fujita H, et al. Multiple chemical sensitivities following intolerance to azo dye in sweets in a 5- year-old girl. Allergol Int 2006;55:203-205.
17. Westerveld GJ, Dekker I, Voss HP, et al. Antioxidant levels in the nasal mucosa of patients with chronic sinusitis and healthy controls. Arch Otolaryngol Head Neck Surg 1997;123: 201-204.
18. Testa B, Mesolella M, Testa D, et al. Glutathione in the upper respiratory tract. Ann Otol Rhinol Laryngol 1995;104:117-119.
19. Testa B, Testa D, Mesolella M, et al. Management of chronic otitis media with effusion: The role of glutathione. Laryngoscope 2001;111:1486-1489.
20. Chinta SJ, Andersen JK. Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: Implications for Parkinson's disease. Free Radical Biol Med 2006;41:1442-1448.
21. Perry TL, Godin DV, Hansen S. Parkinson's disease: A disorder due to nigral glutathione deficiency? Neurosci Lett 1982;33:305-310.
22. Dexter DT, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994;35:38-44.
23. Nakamura K, Wang W, Kang UJ. The role of glutathione in dopaminergic neuronal survival. J Neurochem 1997;69: 1850-1858.
24. Zeevalk GD, Razmpour R, Bernard LP. Glutathione and Parkinson's disease: Is this the elephant in the room? Biomed Pharmacother 2008;62:236-249.
25. Sechi G, Deledda MG, Bua G, et al. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog Neuro-psychopharmacol Biol Psychiatry 1996;20:1159-1170.
26. Hauser RA, Lyons KE, McClain T, et al. Randomized, double- blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord 2009;24:979-983.
27. Intranasal Glutathione in Parkinson's Disease. National Institutes of Health. 2011. Online document at 〈 http://clinicaltrials.gov/ct2/show/ NCT01398748?term= Intranasal+Glutathione+in+Parkinson%E2%80%99s+Disease& rank=1 〉 . Accessed July 26, 2012.